BioRestorative Therapies

129 articles about BioRestorative Therapies

• BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

  5/15/2023

  BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

• A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

  5/12/2023

  Brown Adipose-Derived Stem Cell therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.

• BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City

  5/4/2023

  BioRestorative Therapies, Inc. today announced that CEO Lance Alstodt will participate at the Inaugural EF Hutton Global Conference taking place May 10th to 11th at the Plaza Hotel in New York City.

• BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100

  4/24/2023

  BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease (cLDD).

• BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100

  3/13/2023

  BioRestorative Therapies, Inc . today announced that it has entered into an agreement with the Bruder Consulting & Venture Group.

• BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023

  3/7/2023

  BioRestorative Therapies, Inc.  today announced that it will participate at the Roth 35th Annual Conference being held from March 12 – 14 at The Ritz Carlton, Laguna Niguel in Dana Point, California.

• BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program

  3/2/2023

  BioRestorative Therapies, Inc . today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

• BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

  2/8/2023

  BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.

• BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

  12/6/2022

  BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health.

• BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

  12/5/2022

  BioRestorative Therapies, Inc.(“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive.

• BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022

  11/29/2022

  BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

• BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

  11/16/2022

  BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHK Capital Disruptive Growth Conference in New York City.

• BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

  9/27/2022

  BioRestorative Therapies, Inc. announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare Opportunities Conference being held at The Yale Club in New York City on October 6, 2022.

• BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

  6/30/2022

  BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial evaluating the safety and preliminary efficacy of BRTX-100.

• BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

  6/22/2022

  BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD).

• BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

  6/13/2022

  BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease (cLDD).

• BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

  4/29/2022

  BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), today announced that it is hosting a Principal Investigators Meeting in Uniondale, NY on April 29th - 30th, 2022 for the Company’s lead clinical candidate BRTX-100®, an autologous bone marrow-derived hypoxic cultured stem cell intended for investigational use in its Phase 2 clinical trial to treat chronic lumbar disc disease.

• 

  Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More

  4/25/2022

  It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.

• BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

  4/18/2022

  BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial targeting chronic lumbar disc disease.

• BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

  4/4/2022

  BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced that it has completed testing and certification of its clinical grade cell therapy manufacturing facility.